Guanfacine extended-release (US brand name Intuniv® and generic) is a central alpha2A-adrenergic receptor agonist. It is not a central nervous system (CNS) stimulant. Here is key information about this medication.
Treatment of attention deficit hyperactivity disorder (ADHD) as a monotherapy or as an adjuvant to stimulant medications
Pharmacodynamics and mechanism of action
Guanfacine is a central, selective alpha2A-adrenergic receptor agonist. By “central”, we mean its effects are in the brain. By “selective”, we mean that it has a 20-times higher affinity for the alpha2A receptor subtype than for the alpha2B or alpha2C subtypes.
In children (ages 6-12) and adolescents (ages 13-17)
Starting: 1 mg once daily either in the morning or evening
Titration: Up to 1 mg/week increments Recommended dose: 1 mg to 7 mg (0.05–0.12 mg/kg target weight-based dose range) once daily in the morning or evening based on clinical response and tolerability
Maximum: 4 mg/day in children and 7 mg/day in adolescents
Treatment with guanfacine should not be discontinued abruptly as it may lead to rebound hypertension and an increase in heart rate. The dose should be tapered gradually by no more than 1 mg every 3 to 7 days.
Dosage forms and strengths
Extended-release tablets: 1 mg, 2 mg, 3 mg, and 4 mg
Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Copyright 2016 to 2021, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.